Evidence map›Paper›PMID 29929486›Full record

ArticleBMC cancer2018

Serum MMP-8 and TIMP-1 predict prognosis in colorectal cancer.

Camilla Böckelman, Ines Beilmann-Lehtonen, Tuomas Kaprio, Selja Koskensalo, Taina Tervahartiala, Harri Mustonen, Ulf-Håkan Stenman, Timo Sorsa, Caj Haglund

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in BMC cancer, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 56 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
56citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

56 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. The Role of MMP8 in Cancer: A Systematic Review.International journal of molecular sciences · 2019
    Pooled it
  2. Trial
  3. Trial
  4. Nobiletin in the modified Yiqi Jianpi Decoction enhances the antitumor activity of CD8The Korean journal of physiology & pharmacology : official journal of the Korean Physiological Society and the Korean Society of Pharmacology · 2026
    Article
  5. Review
  6. Article
  7. Article
  8. Article
  9. Article
  10. STAT3 Inhibition to Treat Ulcerative Colitis-Associated Colorectal Cancer.International journal of molecular sciences · 2025
    Article
  11. Article
  12. Article
  13. Review
  14. Article
  15. Article
  16. Review
  17. Review
  18. Article
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Camilla BöckelmanDepartment of Surgery, University of Helsinki and Helsinki University Hospital, P.O. Box 105, Haartmaninkatu 4, Terkon tutkijatilat, 3. krs, FIN-00029 HUS, Helsinki, Finland. camilla.bockelman@helsinki.fi.ORCID http://orcid.org/0000-0002-1628-0305
Ines Beilmann-LehtonenDepartment of Surgery, University of Helsinki and Helsinki University Hospital, P.O. Box 105, Haartmaninkatu 4, Terkon tutkijatilat, 3. krs, FIN-00029 HUS, Helsinki, Finland.
Tuomas KaprioDepartment of Surgery, University of Helsinki and Helsinki University Hospital, P.O. Box 105, Haartmaninkatu 4, Terkon tutkijatilat, 3. krs, FIN-00029 HUS, Helsinki, Finland.
Selja KoskensaloDepartment of Surgery, University of Helsinki and Helsinki University Hospital, P.O. Box 105, Haartmaninkatu 4, Terkon tutkijatilat, 3. krs, FIN-00029 HUS, Helsinki, Finland.
Taina TervahartialaDepartment of Oral and Maxillofacial Diseases, Helsinki University Hospital and Biomedicum Helsinki, P.O. Box 63, Haartmaninkatu 8, 2nd floor, FIN-00014, Helsinki, Finland.
Harri MustonenDepartment of Surgery, University of Helsinki and Helsinki University Hospital, P.O. Box 105, Haartmaninkatu 4, Terkon tutkijatilat, 3. krs, FIN-00029 HUS, Helsinki, Finland.
Ulf-Håkan StenmanDepartment of Clinical Chemistry, University of Helsinki and Helsinki University Hospital, P.O. Box 700, FIN-00029 HUS, Helsinki, Finland.
Timo SorsaDepartment of Oral and Maxillofacial Diseases, Helsinki University Hospital and Biomedicum Helsinki, P.O. Box 63, Haartmaninkatu 8, 2nd floor, FIN-00014, Helsinki, Finland.
Caj HaglundDepartment of Surgery, University of Helsinki and Helsinki University Hospital, P.O. Box 105, Haartmaninkatu 4, Terkon tutkijatilat, 3. krs, FIN-00029 HUS, Helsinki, Finland.

Funding

Competitive State Research Financing of the Expert Responsibility Area of Turku University Hospital and Vaasa Central Hospital 101032
6 · The paper itself

Abstract

backgroundAlmost all of the extracellular matrix (ECM) components can be degraded by the endoproteinases matrix metalloproteinases (MMPs). Important regulators of MMPs, and thereby of the extracellular environment, are tissue inhibitors of metalloproteinases (TIMPs), and especially TIMP-1. Early tumor development, as well as distant metastasis, may be results of an MMP/TIMP ratio imbalance altering the ECM. MMPs are elevated in several inflammatory conditions. Our aim is to investigate the prognostic role of MMP-8, - 9, and TIMP-1 in colorectal cancer (CRC) and their relationship to inflammation.

methodsWe included 337 colorectal cancer patients and 47 controls undergoing surgery at Helsinki University Hospital in Finland, 1998-2011. Serum levels of MMP-8 and plasma levels of C-reactive protein (CRP) were determined with a time-resolved immunofluorometric assay (IFMA), and MMP-9 and TIMP-1 with commercial enzyme-linked immunosorbent assay (ELISA) kits. Association and correlation analyses were performed with the Mann-Whitney U, Kruskal-Wallis, and Spearman rank correlation tests. Survival curves were constructed according to the Kaplan-Meier method and compared with the log-rank test.

resultsAmong patients with advanced disease, serum levels of MMP-8 and TIMP-1 were elevated. CRC patients with high MMP-8 (HR (hazard ratio) 1.72, 95% confidence interval (CI) 1.17-2.52, P = 0.005) and those with high TIMP-1 (HR 1.80, 95% CI 1.23-2.64, P = 0.002) had worse prognoses. MMP-9 level failed to serve as a prognostic factor. In multivariable survival analysis, Dukes stage, and low MMP-9/TIMP-1 molar ratio (HR 0.46, 95% CI 0.33-0.98, P = 0.042) were independently predicted prognosis. A weak correlation between CRP and MMP-8 (r

conclusionsMMP-8 and TIMP-1 in serum, but not MMP-9, identified CRC patients with bad prognosis. Among patients showing no systemic inflammatory response, MMP-8 and TIMP-1 may associate with poor prognosis.

Indexed as

AgedColorectal NeoplasmsC-Reactive ProteinFemaleHumansMaleMatrix Metalloproteinase 8Matrix Metalloproteinase 9Middle AgedPrognosisProportional Hazards ModelsTissue Inhibitor of Metalloproteinase-1C-Reactive ProteinMatrix Metalloproteinase 8Matrix Metalloproteinase 9MMP8 protein, humanTIMP1 protein, humanTissue Inhibitor of Metalloproteinase-1Colon cancerColorectal cancerMMP-8MMP-9PrognosisSurvivalTIMP-1

Identifiers

PMID29929486
PMCPMC6013876

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.